Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-11

Clinical Trial Update: Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 extension study update for abaloparatide in postmenopausal osteoporosis, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abaloparatide (abaloparatide)

Snippet

Sponsor: Radius Health, Inc. | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2020-12-11